Pharmacological enhancement of exposure-based treatment in PTSD: A qualitative review

European Journal of Psychotraumatology

Volumn 4, Issue SUPPL., 2013, Pages

  de Kleine, Rianne A ^a,b,c   Rothbaum, Barbara O ^d   van Minnen, Agnes ^a,b,c  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b Overwaal   (Netherlands)

^c NijCare   (Netherlands)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cognitive enhancers; Exposure therapy; Posttraumatic stress disorder; Treatment efficacy

Indexed keywords

EID: 84898679837     PISSN: None     EISSN: 20008066     Source Type: Journal    
DOI: 10.3402/ejpt.v4i0.21626     Document Type: Review

References (79)

1. Aerni, A., Traber, R., Hock, C., Roozendaal, B., Schelling, G., Papassotiropoulos, A., et al. (2004). Low-dose cortisol for symptoms of posttraumatic stress disorder. American Journal of Psychiatry, 161(8), 1488-1490.
2. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: American Psychiatric Press.
3. Arntz, A., Tiesema, M., & Kindt, M. (2007). Treatment of PTSD: A comparison of imaginal exposure with and without imagery rescripting. Journal of Behavior Therapy and Experimental Psychiatry, 38(4), 345-370.
4. Bisson, J., & Andrew, M. (2007). Psychological treatment of posttraumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews (3), CD003388.
5. Bontempo, A., Panza, K. E., & Bloch, M. H. (2012). D-cycloserine augmentation of behavioral therapy for the treatment of anxiety disorders: A meta-analysis. Journal of Clinical Psychiatry, 73(4), 533-537.
6. Bouso, J. C., Doblin, R., Farre, M., Alcazar, M. A., & Gomez-Jarabo, G. (2008). MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. Journal of Psychoactive Drugs, 40(3), 225-236.
7. Bouton, M. E. (1993). Context, time, and memory retrieval in the interference paradigms of Pavlovian learning. Psychological Bulletin, 114(1), 80-99.
8. Bradley, R., Greene, J., Russ, E., Dutra, L., & Westen, D. (2005). A multidimensional meta-analysis of psychotherapy for PTSD. American Journal of Psychiatry, 162(2), 214-227.
9. Brunet, A., Orr, S. P., Tremblay, J., Robertson, K., Nader, K., & Pitman, R. K. (2008). Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. Journal of Psychiatric Research, 42(6), 503-506.
10. Brunet, A., Poundja, J., Tremblay, J., Bui, E., Thomas, E., Orr, S. P., et al. (2011). Trauma reactivation under the influence of propranolol decreases posttraumatic stress symptoms and disorder: 3 open-label trials. Journal of Clinical Psychopharmacology, 31(4), 547-550.
11. Cami, J., Farre, M., Mas, M., Roset, P. N., Poudevida, S., Mas, A., et al. (2000). Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): Psychomotor performance and subjective effects. Journal of Clinical Psychopharmacology, 20(4), 455-466.
12. Choi, D. C., Rothbaum, B. O., Gerardi, M., & Ressler, K. J. (2010). Pharmacological enhancement of behavioral therapy: Focus on posttraumatic stress disorder. Current Topics in Behavioral Neurosciences, 2, 279-299.
13. Craske, M. G., Kircanski, K., Zelikowsky, M., Mystkowski, J., Chowdhury, N., & Baker, A. (2008). Optimizing inhibitory learning during exposure therapy. Behaviour Research and Therapy, 46(1), 5-27.
14. Davidson, J., Pearlstein, T., Londborg, P., Brady, K. T., Rothbaum, B., Bell, J., et al. (2001). Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: Results of a 28-week double-blind, placebo-controlled study. American Journal of Psychiatry, 158(12), 1974-1981.
15. Davis, H. P., & Squire, L. R. (1984). Protein synthesis and memory: A review. Psychological Bulletin, 96(3), 518-559.
16. de Kleine, R. A., Hendriks, G.-J., Kusters, W. J. C., Broekman, T. G., & van Minnen, A. (2012). A randomized placebo-controlled trial of d-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biological Psychiatry, 71(11), 962-968.
17. de Quervain, D. J., Aerni, A., Schelling, G., & Roozendaal, B. (2009). Glucocorticoids and the regulation of memory in health and disease. Frontiers in Neuroendocrinology, 30(3), 358-370.
18. de Quervain, D. J., Bentz, D., Michael, T., Bolt, O. C., Wiederhold, B. K., Margraf, J., et al. (2011). Glucocorticoids enhance extinction-based psychotherapy. Proceedings of the National Academy of Sciences of the United States of America, 108(16), 6621-6625.
19. Debiec, J., & Ledoux, J. E. (2004). Disruption of reconsolidation but not consolidation of auditory fear conditioning by noradrenergic blockade in the amygdala. Neuroscience, 129(2), 267-272.
20. Dumont, G. J., Sweep, F. C., van der Steen, R., Hermsen, R., Donders, A. R., Touw, D. J., et al. (2009). Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Social Neuroscience, 4(4), 359-366.
21. Dumont, G. J., & Verkes, R. J. (2006). A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers. Journal of Psychopharmacology, 20(2), 176-187.
22. Dunlop, B. W., Mansson, E., & Gerardi, M. (2012). Pharmacological innovations for posttraumatic stress disorder and medication-enhanced psychotherapy. Current Pharmaceutical Design, 18(35), 5645-5658.
23. Farach, F. J., Pruitt, L. D., Jun, J. J., Jerud, A. B., Zoellner, L. A., & Roy-Byrne, P. P. (2012). Pharmacological treatment of anxiety disorders: Current treatments and future directions. Journal of Anxiety Disorders, 26(8), 833-843.
24. Foa, E. B., Hembree, E. A., Cahill, S. P., Rauch, S. A. M., Riggs, D. S., Feeny, N. C., et al. (2005). Randomized trial of prolonged exposure for posttraumatic stress disorder with and without cognitive restructuring: Outcome at academic and community clinics. Journal of Consulting and Clinical Psychology, 73(5), 953-964.
25. Foa, E. B., Hembree, E. A., & Rothbaum, B. O. (2007). Prolonged exposure therapy for PTSD: Emotional processing of traumatic experiences: Therapist guide. New York: Oxford University Press.
26. Foa, E. B., & Rothbaum, B. O. (1998). Treating the trauma of rape: Cognitive-behavioral therapy for PTSD. New York: Guilford Press.
27. Green, A. R., Marsden, C., & Fone, K. (2008). MDMA as a clinical tool: A note of caution. A response to Sessa and Nutt. Journal of Psychopharmacology, 22(8), 929-931.
28. Green, A. R., Mechan, A. O., Elliott, J. M., O'Shea, E., & Colado, M. I. (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacological Reviews, 55(3), 463-508.
29. Guastella, A., Dadds, M., Lovibond, P., Mitchell, P., & Richardson, R. (2007). A randomized controlled trial of the effect of d-cycloserine on exposure therapy for spider fear. Journal of Psychiatric Research, 41(6), 466-471.
30. Hardman, J., & Limbird, L. (2001). Goodman & Gilman's pharmacological basis of therapeutics (10th ed.). New York: McGraw Hill.
31. Hofmann, S. G., Meuret, A. E., Smits, J. A. J., Simon, N. M., Pollack, M. H., Eisenmenger, K., et al. (2006). Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Archives of General Psychiatry, 63(3), 298-304.
32. Hysek, C. M., Domes, G., & Liechti, M. E. (2012). MDMA enhances "mind reading" of positive emotions and impairs "mind reading" of negative emotions. Psychopharmacology, 222(2), 293-302.
33. Hysek, C. M., Simmler, L. D., Nicola, V. G., Vischer, N., Donzelli, M., Krähenbühl, S., et al. (2012). Duloxetine inhibits effects of MDMA ("Ecstasy") and in humans in a randomized placebocontrolled laboratory study. PLoS ONE, 7(5), 36476.
34. Johansen, P. O., & Krebs, T. S. (2009). How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale. Journal of Psychopharmacology, 23(4), 389-391.
35. Kehle-Forbes, S. M., Polusny, M. A., MacDonald, R., Murdoch, M., Meis, L. A., & Wilt, T. J. (2012). A systematic review of the efficacy of adding nonexposure components to exposure therapy for posttraumatic stress disorder. Psychological Trauma: Theory, Research, Practice, and Policy, 5(4), 317-322.
36. Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Archives of General Psychiatry, 62(6), 593-602.
37. Kindt, M., & Soeter, M. (2013). Reconsolidation in a human fear conditioning study: A test of extinction as updating mechanism. Biological Psychology, 92(1), 43-50.
38. Kindt, M., Soeter, M., & Vervliet, B. (2009). Beyond extinction: Erasing human fear responses and preventing the return of fear. Nature Neuroscience, 12(3), 256-258.
39. Kolbrich, E. A., Goodwin, R. S., Gorelick, D. A., Hayes, R. J., Stein, E. A., & Huestis, M. A. (2008). Physiological and subjective responses to controlled oral 3,4-methylene dioxymethamphetamine administration. Journal of Clinical Psychopharmacology, 28(4), 432-440.
40. Kushner, M., Kim, S., Donahue, C., Thuras, P., Adson, D., Kotlyar, M., et al. (2007). D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biological Psychiatry, 62(8), 835-838.
41. Ledgerwood, L., Richardson, R., & Cranney, J. (2003). Effects of D-cycloserine on extinction of conditioned freezing. Behavioral Neuroscience, 117(2), 341-349.
42. LeDoux, J. E. (1995). Emotion: Clues from the brain. Annual Review of Psychology, 46, 209-235.
43. Liechti, M. E., Baumann, C., Gamma, A., & Vollenweider, F. X. (2000). Acute psychological effects of 3,4-methylenedioxy methamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology, 22(5), 513-521.
44. Litz, B. T., Salters-Pedneault, K., Steenkamp, M. M., Hermos, J. A., Bryant, R. A., Otto, M. W., et al. (2012). A randomized placebo-controlled trial of d-cycloserine and exposure therapy for posttraumatic stress disorder. Journal of Psychiatric Research, 11, 11.
45. Lonergan, M. H., Olivera-Figueroa, L. A., Pitman, R. K., & Brunet, A. (2012). Propranolol's effects on the consolidation and reconsolidation of long-term emotional memory in healthy participants: A meta-analysis. Journal of Psychiatry and Neuroscience, 37(6), 120111.
46. MacDonald, E., Dadds, M. R., Brennan, J. L., Williams, K., Levy, F., & Cauchi, A. J. (2011). A review of safety, sideeffects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology, 36(8), 1114-1126.
47. Milekic, M. H., & Alberini, C. M. (2002). Temporally graded requirement for protein synthesis following memory reactivation. Neuron, 36(3), 521-525.
48. Mills, K. L., Teesson, M., Back, S. E., Brady, K. T., Baker, A. L., Hopwood, S., et al. (2012). Integrated exposure-based therapy for co-occurring posttraumatic stress disorder and substance dependence: A randomized controlled trial. JAMA, 308(7), 690-699.
49. Mills, K. L., Teesson, M., Ross, J., & Peters, L. (2006). Trauma, PTSD, and substance use disorders: Findings from the Australian National Survey of Mental Health and Well-Being. American Journal of Psychiatry, 163(4), 652-658.
50. Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011). The safety and efficacy of {-/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study. Journal of Psychopharmacology, 25(4), 439-452.
51. Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., Martin, S. F., Yazar-Klosinski, B., et al. (2013). Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: A prospective long-term follow-up study. Journal of Psychopharmacology, 27(1), 28-39.
52. Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008). A metaanalysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biological Psychiatry, 63(12), 1118-1126.
53. Oehen, P., Traber, R., Widmer, V., & Schnyder, U. (2013). A randomized, controlled pilot study of MDMA (93,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). Journal of Psychopharmacology, 27(1), 40-52.
54. Olff, M., Langeland, W., Witteveen, A., & Denys, D. (2010). A psychobiological rationale for oxytocin in the treatment of posttraumatic stress disorder. CNS Spectrum, 15(8), 522-530.
55. Otto, M.W., Tolin, D. F., Simon, N. M., Pearlson, G. D., Basden, S., Meunier, S. A., et al. (2010). Efficacy of D-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biological Psychiatry, 67(4), 365-370.
56. Parsons, R. G., & Ressler, K. J. (2013). Implications of memory modulation for post-traumatic stress and fear disorders. Nature Neuroscience, 16(2), 146-153.
57. Phelps, E. A., Delgado, M. R., Nearing, K. I., & LeDoux, J. E. (2004). Extinction learning in humans: Role of the amygdala and vmPFC. Neuron, 43(6), 897-905.
58. Powers, M. B., Halpern, J. M., Ferenschak, M. P., Gillihan, S. J., & Foa, E. B. (2010). A meta-analytic review of prolonged exposure for posttraumatic stress disorder. Clinical Psychology Review, 30(6), 635-641.
59. Resick, P. A., Galovski, T. E., O'Brien Uhlmansiek, M., Scher, C. D., Clum, G. A., & Young-Xu, Y. (2008). A randomized clinical trial to dismantle components of cognitive processing therapy for posttraumatic stress disorder in female victims of interpersonal violence. Journal of Consulting and Clinical Psychology, 76(2), 243-258.
60. Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., et al. (2004). Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobic individuals to facilitate extinction of fear. Archives of General Psychiatry, 61(11), 1136-1144.
61. Richardson, R., Ledgerwood, L., & Cranney, J. (2004). Facilitation of fear extinction by D-cycloserine: Theoretical and clinical implications. Learning & Memory, 11(5), 510-516.
62. Rothbaum, B. O., Cahill, S. P., Foa, E. B., Davidson, J. R. T., Compton, J., Connor, K. M., et al. (2006). Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorder. Journal of Traumatic Stress, 19(5), 625-638.
63. Schneier, F. R., Neria, Y., Pavlicova, M., Hembree, E., Suh, E. J., Amsel, L., et al. (2012). Combined prolonged exposure therapy and paroxetine for PTSD related to the World Trade Center attack: A randomized controlled trial. American Journal of Psychiatry, 169(1), 80-88.
64. Schnurr, P. P., Friedman, M. J., Engel, C. C., Foa, E. B., Shea, M., Chow, B. K., et al. (2007). Cognitive behavioral therapy for posttraumatic stress disorder in women: A randomized controlled trial. JAMA, 297(8), 820-830.
65. Sessa, B. (2008). Is there a case for MDMA-assisted psychotherapy in the UK? (vol 21, pg 220, 2007). Journal of Psychopharmacology, 22(6), 699-699.
66. Siegmund, A., Golfels, F., Finck, C., Halisch, A., Räth, D., Plag, J., et al. (2011). D-cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. Journal of Psychiatric Research, 45(8), 1042-1047.
67. Simon, N. M., Connor, K. M., Lang, A. J., Rauch, S. A. M., Krulewicz, S., LeBeau, R. T., et al. (2008). Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. Journal of Clinical Psychiatry, 69(3), 400-405.
68. Smits, J. A. J., Rosenfield, D., Otto, M.W., Powers, M. B., Hofmann, S. G., Telch, M. J., et al. (2013). D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height Phobia. Biological Psychiatry, 16(12), 01094-01093.
69. Soravia, L. M., Heinrichs, M., Aerni, A., Maroni, C., Schelling, G., Ehlert, U., et al. (2006). Glucocorticoids reduce phobic fear in humans. Proceedings of the National Academy of Sciences of the United States of America, 103(14), 5585-5590.
70. Storch, E. A., Merlo, L. J., Bengtson, M., Murphy, T. K., Lewis, M. H., Yang, M. C., et al. (2007). D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. International Clinical Psychopharmacology, 22(4), 230-237.
71. Suris, A., North, C., Adinoff, B., Powell, C. M., & Greene, R. (2010). Effects of exogenous glucocorticoid on combat-related PTSD symptoms. Annals of Clinical Psychiatry, 22(4), 274-279.
72. Suzuki, A., Josselyn, S. A., Frankland, P. W., Masushige, S., Silva, A. J., & Kida, S. (2004). Memory reconsolidation and extinction have distinct temporal and biochemical signatures. The Journal of Neuroscience, 24(20), 4787-4795.
73. Tart, C. D., Handelsman, P. R., Deboer, L. B., Rosenfield, D., Pollack, M. H., Hofmann, S. G., et al. (2013). Augmentation of exposure therapy with post-session administration of d-cycloserine. Journal of Psychiatric Research, 47(2), 168-174.
74. Thompson, M. R., Callaghan, P. D., Hunt, G. E., Cornish, J. L., & McGregor, I. S. (2007). A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy"). Neuroscience, 146(2), 509-514.
75. van Minnen, A., & Hagenaars, M. (2002). Fear activation and habituation patterns as early process predictors of response to prolonged exposure treatment in PTSD. Journal of Traumatic Stress, 15(5), 359-367.
76. van Minnen, A., Harned, M. S., Zoellner, L., & Mills, K. (2012). Examining potential contraindications for prolonged exposure therapy for PTSD. European Journal of Psychotraumatology, 3(10), 25.
77. Walker, D. L., Ressler, K. J., Lu, K. T., & Davis, M. (2002). Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. Journal of Neuroscience, 22(6), 2343-2351.
78. Werner-Seidler, A., & Richardson, R. (2007). Effects of Dcycloserine on extinction: Consequences of prior exposure to imipramine. Biological Psychiatry, 62(10), 1195-1197.
79. Yehuda, R., Bierer, L. M., Pratchett, L., & Malowney, M. (2010). Glucocorticoid augmentation of prolonged exposure therapy: Rationale and case report. European Journal of Psychotraumatology, 1(10), 27.